ARIX — Arix Bioscience Share Price
Last trade - 00:00- £161.80m
- £60.85m
- £0.11m
- 28
- 38
- 85
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.66 | ||
| Price to Tang. Book | 0.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,329.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.34% | ||
| Return on Equity | -11.46% | ||
| Operating Margin | -4725.89% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 1.33 | 0.51 | 0.48 | 0.34 | 0.11 | n/a | n/a | -42.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arix Bioscience plc is a United Kingdom-based global venture capital company. The Company is focused on investing in biotechnology companies to deliver superior risk-adjusted returns to shareholders. The Company is engaged in sourcing, financing, and developing healthcare and life science businesses globally. It focuses on late pre-clinical to clinical-stage ventures and covers a diversified range of therapeutic areas. The Company’s core portfolio includes Artios Pharma Limited, Aura Biosciences, Inc., Disc Medicine Inc., Ensoma, Harpoon Therapeutics, Inc., Imara, Inc., and Iterum Therapeutics Limited. Its program includes AU-011, ART4215 + talazoparib, Bitopertin, HPN328, HPN217, ART0380, ART4215, and DISC-0974. It has approximately 11 clinical trials and is conducting nine pre-clinical studies. The Company’s subsidiaries include Arix Bioscience Holdings Limited, Arix Bioscience, Inc, Arix Capital Management Limited, Arthurian Life Sciences GP Limited, and ALS SPV Limited.
Directors
- Naseem Amin CHM (59)
- Robert Lyne CEO
- Marcus Karia FID
- Mark Chin MDR (39)
- Tim Xu OTH
- James Noble NED
- Axel Wieandt NED
- Michael Bunbury NID (73)
- Trevor Jones NID (77)
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- September 15th, 2015
- Public Since
- February 17th, 2017
- No. of Employees
- 7
- Sector
- Investment Banking & Investment Services
- Industry
- Financials
- Exchange
- London Stock Exchange
- Shares in Issue
- 129,439,179
- Address
- Duke Street House, 50 Duke Street, LONDON, W1K 6JL
- Web
- https://arixbioscience.com/
- Phone
- +44 2072901050
- Auditors
- BDO LLP
Latest News for ARIX
Upcoming Events for ARIX
Half Year 2023 Arix Bioscience PLC Earnings Release
Similar to ARIX
3i
London Stock Exchange
450
London Stock Exchange
Abrdn
London Stock Exchange
Adams
London Stock Exchange
Agronomics
London Stock Exchange
FAQ
As of Today at 19:02 UTC, shares in Arix Bioscience are trading at 115.00p. This share price information is delayed by 15 minutes.
Shares in Arix Bioscience last closed at 115.00p and the price had moved by +7.48% over the past 365 days. In terms of relative price strength the Arix Bioscience share price has outperformed the FTSE All Share Index by +4.06% over the past year.
The overall consensus recommendation for Arix Bioscience is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Arix Bioscience does not currently pay a dividend.
Arix Bioscience does not currently pay a dividend.
Arix Bioscience does not currently pay a dividend.
To buy shares in Arix Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 115.00p, shares in Arix Bioscience had a market capitalisation of £148.86m.
Here are the trading details for Arix Bioscience:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: ARIX
Based on an overall assessment of its quality, value and momentum Arix Bioscience is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Arix Bioscience is 172.00p. That is 49.57% above the last closing price of 115.00p.
Analysts covering Arix Bioscience currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arix Bioscience. Over the past six months, its share price has outperformed the FTSE All Share Index by +11%.
As of the last closing price of 115.00p, shares in Arix Bioscience were trading +7.14% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Arix Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 115.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Arix Bioscience's management team is headed by:
- Naseem Amin - CHM
- Robert Lyne - CEO
- Marcus Karia - FID
- Mark Chin - MDR
- Tim Xu - OTH
- James Noble - NED
- Axel Wieandt - NED
- Michael Bunbury - NID
- Trevor Jones - NID